22 citations,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
108 citations,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
68 citations,
May 2012 in “Annals of Oncology” Some breast cancer chemotherapy can cause permanent hair loss.
67 citations,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
59 citations,
August 2018 in “The oncologist” Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
32 citations,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
31 citations,
March 2017 in “Journal of The American Academy of Dermatology” Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.
18 citations,
August 2019 in “Clinical breast cancer” Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
12 citations,
May 2010 in “PubMed” No definitive link between finasteride and male breast cancer, but further research is needed.
9 citations,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
9 citations,
January 2014 in “Annals of Dermatology” Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.
9 citations,
February 2012 in “Social Semiotics” The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.
8 citations,
December 2017 in “Cancer Medicine” Finasteride use may increase the risk of male breast cancer.
7 citations,
March 2019 in “Cancer Epidemiology, Biomarkers & Prevention” Finasteride use is not clearly linked to an increased risk of male breast cancer.
7 citations,
May 2016 in “SpringerPlus” Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
4 citations,
May 2019 in “Journal of Clinical Oncology” Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
4 citations,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
4 citations,
January 2011 in “International Journal of Clinical Medicine” Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
3 citations,
July 2018 in “Cureus” A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.
3 citations,
August 2013 in “Journal of the National Cancer Institute” The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.
2 citations,
March 2021 in “Cutis” Some breast cancer treatments, like taxanes, can cause long-term hair loss.
2 citations,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
January 2023 in “Mastology” Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
September 2003 in “Journal of the Royal Society of Medicine” Understanding breast cancer requires considering both medical advancements and social influences.
15 citations,
June 2014 in “Integrative cancer therapies” Pranic meditation significantly improved mental health and quality of life for breast cancer survivors.
2 citations,
December 2013 in “Cancer Research” Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.
2 citations,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.